Paracetamol IV (Orthopaedic — Opioid-Sparing)
Brand names: Perfalgan
Intravenous paracetamol is a non-opioid analgesic and antipyretic used as a baseline, opioid-sparing component of multimodal analgesia in orthopaedic patients who cannot take oral medication.
Adult dose
Paediatric dose
Dose adjustments
§4.2: 'Severe renal insufficiency: It is recommended, when giving paracetamol to patients with severe renal impairment (creatinine clearance <= 30 ml/min), to reduce the dose and increase the minimum interval between each administration to 6 hours.' 'The minimum interval between each administration in patients with severe renal insufficiency must be at least 6 hours.' §4.4 also lists severe renal insufficiency (creatinine clearance <= 30 ml/min) among the conditions requiring caution. No milligram reduction figure is given in the SPC.
'Cases of severe hepatocellular insufficiency' are an absolute contraindication (§4.3). §4.2: 'Adults with hepatocellular insufficiency, chronic alcoholism, chronic malnutrition (low reserves of hepatic glutathione), dehydration: The maximum daily dose must not exceed 3000 mg.' The posology table separately caps patients over 50 kg 'with additional risk factors for hepatotoxicity' at a maximum daily dose of 3 g (versus 4 g without such risk factors). §4.4 lists hepatocellular insufficiency, chronic alcoholism, chronic malnutrition and dehydration as cautions.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to paracetamol, propacetamol hydrochloride (prodrug of paracetamol) or to any of the excipients listed in section 6.1
- Cases of severe hepatocellular insufficiency
Side effects
- Thrombocytopenia, leucopenia, neutropenia (very rare, <1/10,000)
- Hypersensitivity reaction (very rare) - 'ranging from simple skin rash or urticaria to anaphylactic shock have been reported and require discontinuation of treatment'
- High anion gap metabolic acidosis due to pyroglutamic acidosis (metabolism and nutrition disorders)
- Hypotension (rare); flushing (isolated cases)
- Tachycardia (isolated cases)
- Increased levels of hepatic transaminases (rare)
- Serious skin reactions (very rare); pruritus and erythema (isolated cases)
- Malaise (rare)
- Injection site reactions - 'Frequent adverse reactions at injection site have been reported during clinical trials (pain and burning sensation)'
- Liver damage with doses higher than recommended - 'fulminant hepatitis, hepatic failure, cholestatic hepatitis, cytolytic hepatitis ... usually first seen after two days of drug administration with a peak seen, usually after 4 - 6 days' (§4.4)
Monitoring
- 'In order to avoid the risk of overdose, check that other medicines administered do not contain either paracetamol or propacetamol' - the maximum daily dose in the posology table applies only to patients not receiving other paracetamol-containing products
- 'If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended. The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors'
- 'close monitoring is needed notably at the end of the infusion, regardless of administration route ... particularly for central route infusions, in order to avoid air embolism'
- Watch for clinical signs and symptoms of liver damage, which are 'usually first seen after two days of drug administration with a peak seen, usually after 4 - 6 days'; 'Treatment with antidote should be given as soon as possible'
- Review the need for the IV route daily - 'Prolonged or frequent use is discouraged. It is recommended that a suitable analgesic oral treatment will be used as soon as this route of administration is possible'
Clinical monograph
How it works
Its analgesic and antipyretic action is thought to be mediated centrally, including effects on prostaglandin pathways, with little peripheral anti-inflammatory activity.
Prescribing in practice
- Dose by body weight and reduce in low-weight adults, hepatic impairment, malnutrition or chronic alcohol use to avoid hepatotoxicity, taking care to avoid duplicate paracetamol from other sources.
- Administer as a slow infusion and check no other paracetamol-containing products are being given concurrently.
- Used as the analgesic foundation, it reduces opioid requirements and associated adverse effects after orthopaedic surgery.
Monitoring
Monitor pain scores and cumulative paracetamol intake from all routes, with liver function review if overdose is suspected.
Counselling the patient
- This is a regular background painkiller used to reduce the amount of strong opioid needed.
- Tell the team about any paracetamol-containing tablets you take so doses are not duplicated.
- Report ongoing pain so additional analgesia can be added.
Evidence & guidelines
Paracetamol is recommended as the foundation of multimodal, opioid-sparing analgesia in UK enhanced-recovery and perioperative guidance.
Reference: NICE NG124 (Hip Fracture); ERAS Society Orthopaedic Guidelines; Perfalgan SPC; MHRA Paracetamol Overdose Guidance; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Morphine Milligram Equivalents (MME) Calculator · Pain / Opioids
- Opioid Conversion / Equianalgesic Guide · Pain Management
- Rumack-Matthew Nomogram · Toxicology
- Numeric Rating Scale (NRS) Pain Assessment and Management · Pain Management
- King's College Criteria for Acute Liver Failure · Prognosis
- Kings College Criteria for Paracetamol Toxicity · Hepatology
- Hip Fracture Management · NICE CG124 / BOA 2020
- Distal Radius Fracture · BOA / NICE
- Ankle Fracture Management · BOA / Lauge-Hansen classification
- Metastatic Spinal Cord Compression · NICE CG75 2020
- Open Fracture Management · BOA/BAPRAS 2017
- OrthoPath: Upper Limb ED Triage · OrthoPath ED Tool — ReviseMRCEM.com